Anima Biotech is pioneering Translation Control Therapeutics, a new class of drugs that control protein translation. Our novel drug discovery platform enables a new therapeutic strategy to approach hard or undruggable protein targets where existing methods have failed for decades.
Our platform is enabled by a breakthrough, patented technology. Anima's Protein Synthesis Monitoring (PSM) technology enables for the first time the visualization and monitoring of protein synthesis by ribosomes in living cells in real time. We use this information in specialized high content screening methods to discover molecules that regulate protein translation, correcting problems in over-expression or under-expression of target proteins. The platform is the result of over a decade of development in collaboration with a broad network of 17 leading academia and research institutions that have validated and expanded the scope and reach of our technology.
Anima's drug discovery pipeline is currently focused on four outstanding therapeutic areas where the underlying cause of the disease is closely linked to protein translation: Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (controlling the production of toxic proteins).
Protein translation is a major biological process and the ability to control it opens a new therapeutic strategy for many additional diseases. We seek to maximize the therapeutic potential of our platform by partnering with pharma companies in their drug discovery programs.